1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63154A1D5A77FF183002586390068AD9E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-advocacy-internal-collaboration-partnerships-and-disease-awareness-coordination?opendocument
18
19opendocument
203.232.96.22
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Patient Focused Services Patient Advocacy Groups

Patient Advocacy Internal Collaboration: Partnerships and Disease Awareness Coordination

ID: 5656


Features:

11 Info Graphics

15 Data Graphics

120 Metrics

7 Narratives


Pages/Slides: 33


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Patient Advocacy Internal Collaboration: Partnerships and Disease Awareness Coordination"

STUDY OVERVIEW

Creating and maintaining a patient-centric biopharmaceutical organization requires not just the influence of an Advocacy Team but the influence of all other parts of the organization. This study examines how advocacy teams can improve coordination efforts with internal groups such as Marketing, Medical Affairs, R&D, and Government Affairs.

In particular, this study spotlights the mechanics of partnerships with Patient Advocacy Groups, improving health and disease awareness with Patient Advocacy Groups and leveraging telehealth to improve patient centricity. Advocacy leaders can use this research to improve its collaborative efforts with internal stakeholders regarding these topics.

KEY TOPICS

  • Mechanics of Partnerships
  • Vertical and Horizontal Reporting
  • Activities to Build PAG Relationships
  • Patient Journey Involvement and Pandemic Challenges
  • Improving Disease Awareness
  • Disease Awareness Digital Tools and Telehealth

KEY METRICS
  • The goals of Advocacy’s internal partnerships
  • Overall difficulty, in terms of time and effort necessary to complete, for submitting proposals for partnerships with patient advocacy groups; and Reasons for difficulty
  • Vertical reporting structure of patient advocacy functions
  • Effectiveness of various activities designed to help advocacy teams coordinate their relationships with patient advocacy groups
  • Lead / support role of patient advocacy teams in activities throughout the patient journey
  • Benchmark partner’s recent success story that arose from collaborating internally with another function around patient advocacy to impact the lives of patients
  • Benchmark partners’ narratives around adapting to the challenges posed by the COVID-19 pandemic
  • Functions with which advocacy teams partner to develop or implement disease awareness programs
  • Benchmark partners’ successful collaboration stories between marketing and communication
  • Function that holds the budget for the design and implementation of disease awareness programs
  • Benchmark partner’s narrative around patient ad boards
  • Digital tools used by patient advocacy groups that have a positive impact on disease awareness
  • Benchmark partners’ narratives around successful internal collaborations with other functions around patient advocacy to impact the lives of patients
  • Patient advocacy team involvement in improving the telehealth experiences of patients
  • Innovative ways in which patient advocacy teams are leveraging the power of telehealth services
SAMPLE KEY FINDINGS
  • Marketing and Medical Are Key to Disease Awareness: The primary foundation of disease awareness campaigns are Marketing, which provides the resources and channels necessary to disseminate info, and Medical Affairs, which provides the data behind the content.

METHODOLOGY

This study engaged 54 leaders from 44 biopharma organizations via a benchmark survey.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Communications; Biopharmaceutical; Health Care; Energy; Chemical


Companies Profiled:
AbbVie; Bayer; Astellas; Alexion Pharmaceuticals; ApotheCom; Arena Pharmaceuticals; Bluebird Bio; Boehringer Ingelheim; Clovis Oncology; Dermira; Eli Lilly; Forma Therapeutics; Johnson & Johnson; Galapagos; Horizon Therapeutics; Ipsen; Kiniksa Pharmaceuticals; Milestone Pharmaceuticals; Myovant Sciences; Amicus Therapeutics; NexGen Healthcare Communications; Novartis; Novo Nordisk; Orchard Therapeutics; Orion Energy; Genentech; Roche; OTSUKA; Reata Pharmaceuticals; Sangamo Therapeutics; Spark Therapeutics; Sunovion; Syneos Health; Takeda Pharmaceuticals; TG Therapeutics; Theravance; UCB Pharma; United Therapeutics; Wave Life Sciences; Zogenix; Vifor Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.